Aspira and Cleveland Clinic Expand AI Diagnostics Collaboration in Women’s Health

Austin-based Aspira Women’s Health and Cleveland Clinic expanded their strategic collaboration to develop AI-powered diagnostics for women’s health, including ovarian cancer and endometriosis.

The companies said on May 26 that the agreement will support biomarker discovery, translational research, clinical validation, and commercialization efforts tied to noninvasive diagnostic technologies. The collaboration combines Cleveland Clinic’s clinical research infrastructure with Aspira’s AI-enabled multiomic platform.

Under the agreement, the organizations will work on discovering and validating biomarker signatures and developing analytical models intended to improve diagnostic accuracy and clinical utility. The initiative also includes future collaboration around intellectual property, data generation, and clinical research programs.

Mike Buhle, CEO of Aspira Women’s Health, said the partnership strengthens the company’s long-term diagnostics platform strategy and expands its scientific and operational capabilities. Kevin Elias, MD, Cleveland Clinic’s Lilli and Seth Harris Endowed Chair for Ovarian Cancer Research, said combining multiomic biomarkers with AI-driven analytics could improve precision diagnostics in women’s health.